Beijing Immunnotech Applied Science

Beijing Immunotech Applied Science is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of advanced Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet medical needs in oncology, particularly for solid tumors which remain a significant challenge for conventional cell therapies. Its lead research program targets Glypican-3 (GPC3) for the treatment of hepatocellular carcinoma, the most common form of liver cancer. Beyond its lead asset, the company is exploring additional targets such as Mesothelin to expand its pipeline into other solid tumor indications. Immunotech leverages a proprietary technology platform to optimize T-cell engineering and improve therapeutic outcomes in the immunosuppressive tumor microenvironment. The organization is committed to translating cutting-edge immunological research into effective clinical treatments for cancer patients.